Leerink Partnrs Increases Earnings Estimates for Q32 Bio

Q32 Bio Inc. (NASDAQ:QTTB) – Equities research analysts at Leerink Partnrs upped their FY2025 EPS estimates for shares of Q32 Bio in a note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($3.38) per share for the year, up from their previous estimate of ($5.32). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.20) per share. Leerink Partnrs also issued estimates for Q32 Bio’s FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($3.62) EPS and FY2028 earnings at ($2.50) EPS.

Several other analysts have also recently weighed in on QTTB. Raymond James reaffirmed an “outperform” rating and set a $22.00 price objective (down from $90.00) on shares of Q32 Bio in a research report on Wednesday. Leerink Partners reaffirmed a “market perform” rating and issued a $9.00 price target (down from $68.00) on shares of Q32 Bio in a research note on Wednesday. Guggenheim lowered Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday. Piper Sandler reduced their target price on shares of Q32 Bio from $85.00 to $20.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, BMO Capital Markets lowered their price target on shares of Q32 Bio from $64.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.86.

Q32 Bio Price Performance

Shares of NASDAQ QTTB opened at $3.70 on Friday. Q32 Bio has a 1 year low of $3.67 and a 1 year high of $53.79. The stock has a market capitalization of $45.07 million, a P/E ratio of -0.26 and a beta of -0.46. The company’s 50-day moving average is $36.81 and its 200 day moving average is $34.18. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Franklin Resources Inc. bought a new stake in shares of Q32 Bio during the third quarter valued at approximately $225,000. Barclays PLC lifted its holdings in shares of Q32 Bio by 105.2% during the third quarter. Barclays PLC now owns 10,443 shares of the company’s stock valued at $465,000 after purchasing an additional 5,353 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Q32 Bio by 22.4% during the third quarter. Geode Capital Management LLC now owns 131,768 shares of the company’s stock valued at $5,881,000 after buying an additional 24,114 shares during the last quarter. Jane Street Group LLC bought a new stake in Q32 Bio in the 3rd quarter worth about $733,000. Finally, State Street Corp raised its position in Q32 Bio by 35.5% in the 3rd quarter. State Street Corp now owns 110,164 shares of the company’s stock worth $4,916,000 after buying an additional 28,865 shares during the last quarter. 31.32% of the stock is owned by hedge funds and other institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.